Suppr超能文献

B7 家族分子在血液恶性肿瘤中的作用。

The role of B7 family molecules in hematologic malignancy.

机构信息

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

出版信息

Blood. 2013 Jan 31;121(5):734-44. doi: 10.1182/blood-2012-10-385591. Epub 2012 Dec 6.

Abstract

The B7 family consists of structurally related, cell-surface proteins that regulate immune responses by delivering costimulatory or coinhibitory signals through their ligands. Eight family members have been identified to date including CD80 (B7-1), CD86 (B7-2), CD274 (programmed cell death-1 ligand [PD-L1]), CD273 (programmed cell death-2 ligand [PD-L2]), CD275 (inducible costimulator ligand [ICOS-L]), CD276 (B7-H3), B7-H4, and B7-H6. B7 ligands are expressed on both lymphoid and nonlymphoid tissues. The importance of the B7 family in regulating immune responses is clear from their demonstrated role in the development of immunodeficiency and autoimmune diseases. Manipulation of the signals delivered by B7 ligands shows great potential in the treatment of cancers including leukemias and lymphomas and in regulating allogeneic T-cell responses after stem cell transplantation.

摘要

B7 家族由结构相关的细胞表面蛋白组成,通过其配体传递共刺激或共抑制信号来调节免疫反应。迄今为止,已经鉴定出 8 个家族成员,包括 CD80(B7-1)、CD86(B7-2)、CD274(程序性细胞死亡 1 配体[PD-L1])、CD273(程序性细胞死亡 2 配体[PD-L2])、CD275(诱导共刺激配体[ICOS-L])、CD276(B7-H3)、B7-H4 和 B7-H6。B7 配体在淋巴组织和非淋巴组织上均有表达。B7 家族在调节免疫反应中的重要性从其在免疫缺陷和自身免疫性疾病发展中的作用中显而易见。B7 配体传递信号的操纵在治疗癌症(包括白血病和淋巴瘤)和调节干细胞移植后同种异体 T 细胞反应方面显示出巨大的潜力。

相似文献

1
The role of B7 family molecules in hematologic malignancy.
Blood. 2013 Jan 31;121(5):734-44. doi: 10.1182/blood-2012-10-385591. Epub 2012 Dec 6.
2
The B7 family of immune-regulatory ligands.
Genome Biol. 2005;6(6):223. doi: 10.1186/gb-2005-6-6-223. Epub 2005 May 31.
4
The B7 family revisited.
Annu Rev Immunol. 2005;23:515-48. doi: 10.1146/annurev.immunol.23.021704.115611.
5
B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
Front Oncol. 2021 Mar 31;11:647526. doi: 10.3389/fonc.2021.647526. eCollection 2021.
6
Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.
Reprod Biol Endocrinol. 2021 Jul 21;19(1):114. doi: 10.1186/s12958-021-00800-6.
7
The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
Int J Mol Sci. 2023 Mar 21;24(6):5931. doi: 10.3390/ijms24065931.
8
New B7 Family Checkpoints in Human Cancers.
Mol Cancer Ther. 2017 Jul;16(7):1203-1211. doi: 10.1158/1535-7163.MCT-16-0761.
9
The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.
Annu Rev Immunol. 2002;20:29-53. doi: 10.1146/annurev.immunol.20.091101.091806. Epub 2001 Oct 4.
10
Regulation of Immunity by Butyrophilins.
Annu Rev Immunol. 2016 May 20;34:151-72. doi: 10.1146/annurev-immunol-041015-055435. Epub 2016 Jan 11.

引用本文的文献

1
Targeting the Exon2 splice cis-element in PD-1 and its effects on lymphocyte function.
PLoS One. 2025 Sep 8;20(9):e0331468. doi: 10.1371/journal.pone.0331468. eCollection 2025.
3
PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression.
J Immunol Res. 2024 Jul 2;2024:3145695. doi: 10.1155/2024/3145695. eCollection 2024.
5
New Insights into Roles of IL-7R Gene as a Therapeutic Target Following Intracerebral Hemorrhage.
J Inflamm Res. 2024 Jan 18;17:399-415. doi: 10.2147/JIR.S438205. eCollection 2024.
6
Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Animal Model Exp Med. 2023 Oct;6(5):464-473. doi: 10.1002/ame2.12355. Epub 2023 Oct 18.
7
Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors.
JTO Clin Res Rep. 2023 Sep 9;4(10):100573. doi: 10.1016/j.jtocrr.2023.100573. eCollection 2023 Oct.
9
First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators.
RSC Med Chem. 2023 Aug 1;14(9):1767-1777. doi: 10.1039/d3md00150d. eCollection 2023 Sep 19.
10
Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials.
Front Oncol. 2023 May 1;13:1153066. doi: 10.3389/fonc.2023.1153066. eCollection 2023.

本文引用的文献

1
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.
2
Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.
J Clin Oncol. 2013 Jan 10;31(2):256-62. doi: 10.1200/JCO.2011.39.9881. Epub 2012 Oct 8.
3
An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
J Immunol. 2012 Sep 1;189(5):2290-9. doi: 10.4049/jimmunol.1103495. Epub 2012 Jul 30.
4
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.
Blood. 2012 Sep 13;120(11):2269-79. doi: 10.1182/blood-2012-05-430470. Epub 2012 Jul 5.
5
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
6
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
9
ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice.
J Immunol. 2012 Feb 1;188(3):1064-74. doi: 10.4049/jimmunol.1101303. Epub 2012 Jan 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验